Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | PSIP1 | O75475 | 2/20 | 0.39 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7865 | 0.81 | ALDH1A1 (0.61) | ALDH1A1CYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL23351954 | 0.80 | PSIP1 (0.61) | ENPP2PTGS2ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL2376239 | 0.79 | ENPP2 (0.72) | ENPP2PTGS2 | |
| SCHEMBL27277400 | 0.77 | CA2 (0.57) | ALDH1A1GAAPSIP1 | |
| SCHEMBL14393403 | 0.76 | ENPP2 (0.50) | ENPP2PTGS2ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL1751990 | 0.76 | ENPP2 (0.50) | ENPP2PTGS2TGM2 | |
| SCHEMBL758698 | 0.76 | PLCG1 (0.67) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10823106 | 0.76 | CA2 (0.57) | ENPP2ALDH1A1CYP3A4GAA | |
| SCHEMBL6219614 | 0.76 | ALDH1A1 (0.54) | ALDH1A1CYP3A4 | |
| SCHEMBL2218853 | 0.76 | GAA (0.61) | ALDH1A1CYP3A4CYP2C9GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866277-B1 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8680152-B2 | Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain | VIROBAY, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8450373-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-1865940-B1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20120282267-A1 | CATHEPSIN INHIBITORS FOR THE TREATMENT OF BONE CANCER AND BONE CANCER PAIN | VIROBAY, INC. (US) | 2012-11-08 | — | — | US | disclosed |
| EP-2511257-A2 | Alpha ketoamide compounds as cysteine protease inhibitors | ViroBay, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120190714-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | APPLERA CORPORATION (US) | 2012-07-26 | — | — | US | disclosed |
| US-8013183-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100305331-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7696250-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090170909-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7488848-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080287446-A1 | Sulfonyl Containing Compounds as Cysteine Protease Inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2008-11-20 | — | — | US | disclosed |
| CN-101180266-A | Alpha ketoamide compounds as cysteine protease inhibitors | APPLERA CORP (US) | 2008-05-14 | — | — | CN | disclosed |
| US-20070021353-A1 | Alpha ketoamide compounds as cysteine protease inhibitors | APPLERA CORPORATION (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190714-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | ENPP2 1571/4885PTGS2 1226/4885ALDH1A1 2023/4885 |
| US-20080287446-A1 | Sulfonyl Containing Compounds as Cysteine Protease Inhibitors | CTSS, CTSF, CTSB | ENPP2 756/4885PTGS2 2610/4885ALDH1A1 2741/4885 |
| US-20090170909-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | ENPP2 1571/4885PTGS2 1226/4885ALDH1A1 2023/4885 |
| US-20070021353-A1 | Alpha ketoamide compounds as cysteine protease inhibitors | CTSS, CTSF, CTSB | ENPP2 1571/4885PTGS2 1226/4885ALDH1A1 2023/4885 |
| US-20120282267-A1 | CATHEPSIN INHIBITORS FOR THE TREATMENT OF BONE CANCER AND BONE CANCER PAIN | CTSS, CTSB, CTSK | ENPP2 416/4885PTGS2 404/4885ALDH1A1 3463/4885 |
| US-20100305331-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | ENPP2 1571/4885PTGS2 1226/4885ALDH1A1 2023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.